Skip to content

R&D at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.65B+17.4%
Eli Lilly logo
Eli LillyLLY
$3.51B+28.4%
Amgen logo
AmgenAMGN
$1.72B+15.7%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$343.97M+67.2%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$33.53M-8.0%
IDEAYA Biosciences, Inc. logo
IDEAYA Biosciences, Inc.IDYA
$95.73M+35.0%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$4.69B+1,196%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: Erasca, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Erasca, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Erasca, Inc.'s R&D?
Erasca, Inc. (ERAS) reported R&D of $27.27M in Q1 2026.
How has Erasca, Inc.'s R&D changed year-over-year?
Erasca, Inc.'s R&D increased by 5.0% year-over-year, from $25.97M to $27.27M.
What is the long-term trend for Erasca, Inc.'s R&D?
Over 4 years (2021 to 2025), Erasca, Inc.'s R&D has grown at a 5.9% compound annual growth rate (CAGR), from $73.92M to $92.85M.
What does R&D mean?
Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.